A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-012)

NCT01936688 Phase 3 WITHDRAWN

This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.

Details

Lead sponsor	Sun Pharmaceutical Industries Limited
Phase	Phase 3
Status	WITHDRAWN
Start date	2013-09
Completion	2018-08

Conditions

• Plaque-type Psoriasis

Interventions

• MK-3222 200 mg
• MK-3222 100 mg
• Placebo to MK-3222
• Placebo to Etanercept
• Etanercept 50 mg

Primary outcomes

• Proportion of Participants Achieving a Psoriasis Area Severity Index 75% (PASI-75) at Week 12 — Week 12
• Proportion of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 — Baseline, Week 12